Christoph Ruwwe‐Glösenkamp
A5070298014- COVID-19 Clinical Research Studies
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Respiratory Support and Mechanisms
- SARS-CoV-2 and COVID-19 Research
- Long-Term Effects of COVID-19
- Lung Cancer Diagnosis and Treatment
- Pleural and Pulmonary Diseases
- Lung Cancer Research Studies
- Tracheal and airway disorders
- COVID-19 diagnosis using AI
- Asthma and respiratory diseases
- Congenital Diaphragmatic Hernia Studies
- Allergic Rhinitis and Sensitization
- Nosocomial Infections in ICU
- Respiratory viral infections research
- Lung Cancer Treatments and Mutations
- Rabies epidemiology and control
- COVID-19 and Mental Health
- Liver Diseases and Immunity
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Herpesvirus Infections and Treatments
- Antifungal resistance and susceptibility
- Pneumothorax, Barotrauma, Emphysema
- Occupational and environmental lung diseases
- Respiratory and Cough-Related Research
Charité - Universitätsmedizin Berlin
2017-2022
Humboldt-Universität zu Berlin
2018-2022
Freie Universität Berlin
2018-2022
COVID-19 is highly variable in its clinical presentation, ranging from asymptomatic infection to severe organ damage and death. We characterized the time-dependent progression of disease 139 inpatients by measuring 86 accredited diagnostic parameters, such as blood cell counts enzyme activities, well untargeted plasma proteomes at 687 sampling points. report an initial spike a systemic inflammatory response, which gradually alleviated followed protein signature indicative tissue repair,...
Abstract Purpose Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide causing a global health emergency. Pa-COVID-19 aims to provide comprehensive data on clinical course, pathophysiology, immunology and outcome of COVID-19, identify prognostic biomarkers, scores, therapeutic targets for improved management preventive interventions. Methods is prospective observational cohort study patients with confirmed SARS-CoV-2 infection treated at Charité -...
Abstract Coronavirus disease 2019 (COVID-19) is caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Type I interferons are important in the defense of viral infections. Recently, neutralizing IgG auto-antibodies against type were found patients COVID-19 infection. Here, we analyzed expression CD169/SIGLEC1, a well described downstream molecule interferon signaling, and increased monocytic CD169/SIGLEC1 levels mild, COVID-19, compared to disease. We...
Global healthcare systems are challenged by the COVID-19 pandemic. There is a need to optimize allocation of treatment and resources in intensive care, as clinically established risk assessments such SOFA APACHE II scores show only limited performance for predicting survival severely ill patients. Additional tools also needed monitor treatment, including experimental therapies clinical trials. Comprehensively capturing human physiology, we speculated that proteomics combination with new...
Abstract Background Increasing evidence suggests that secondary sclerosing cholangitis (SSC), which can lead to cirrhosis or liver failure, may be a hepatobiliary long-term complication of COVID-19. The aim this study was estimate the frequency and outcome COVID-19 sequela identify possible risk factors. Methods This observational study, conducted at University Hospital Charité Berlin Unfallkrankenhaus Berlin, Germany, involved hospitalized patients with pneumonia, including 1082 ventilated...
Purpose: Lung volume reduction using one-way endobronchial valves is a bronchoscopic treatment for patients with severe emphysema without collateral ventilation between the target lobe and ipsilateral lobe(s). CT-scan fissure analysis often used as surrogate to predict absence of ventilation. We aimed evaluate predictive value completeness score (FCS) compared functional Chartis measurement provide cut-off values FCS in patient selection. Patients Methods: Multicenter study eligible valves....
Adequate patient allocation is pivotal for optimal resource management in strained healthcare systems, and requires detailed knowledge of clinical virological disease trajectories. The purpose this work was to identify risk factors associated with need invasive mechanical ventilation (IMV), analyse viral kinetics patients without IMV provide a comprehensive description course.A cohort 168 hospitalised adult COVID-19 enrolled prospective observational study at large European tertiary care...
Abstract Introduction Recurrent pleural effusion is a common cause of dyspnoea, cough and chest pain during the course malignant diseases. Chemical pleurodesis had been only definitive treatment option until two decades ago. Indwelling catheters (IPC) emerged as an alternative, not assuring immediate symptom relief but also potentially leading to in absence sclerosing agents. Methods In this single-centre retrospective observational study patient characteristics, procedural variables outcome...
Background Recurrent pleural effusion is a common cause of dyspnoea, cough and chest pain during the course infectious pleurisy non-malignant diseases like congestive heart failure (CHF) or liver cirrhosis with hepatic hydrothorax (HH). With regard to chronic character underlying diseases, indwelling catheters (IPC) are increasingly used, not only assuring immediate symptom relief but also potentially leading pleurodesis without sclerosing agents. Patients methods In this single-centre...
Background Endoscopic lung volume reduction (ELVR) with valves has been suggested to be the key strategy for patients severe emphysema and concomitant low diffusing capacity of carbon monoxide ( D LCO ). However, robust evidence is still missing. We therefore aim compare clinical outcomes in relation treated ELVR. Methods assessed at baseline 3 months follow-up compared pre- postprocedural pulmonary function test, quality life, exercise adverse events. This a retrospective subanalysis...
Dexamethasone has become the standard of care for severe coronavirus disease 2019 (COVID-19), but its virological impact is poorly understood. The objectives this work were to characterize kinetics acute respiratory syndrome 2 (SARS-CoV-2) concentration in upper tract (URT) and antibody response patients with (D+) without (D-) dexamethasone treatment.Data biosamples from hospitalized COVID-19, enrolled between 4th March 11th December 2020 a prospective observational study, analysed....
Abstract COVID-19 is highly variable in its clinical presentation, ranging from asymptomatic infection to severe organ damage and death. There an urgent need for predictive markers that can guide decision-making, inform about the effect of experimental therapies, point novel therapeutic targets. Here, we characterize time-dependent progression through different stages disease, by measuring 86 accredited diagnostic parameters plasma proteomes at 687 sampling points, a cohort 139 patients...
<b><i>Background:</i></b> Robust clinical evidence on the efficacy and safety of endoscopic lung volume reduction (ELVR) with one-way valves in patients severe emphysema chronic hypercapnic respiratory failure is lacking. <b><i>Objective:</i></b> The aim this study was to compare patient characteristics, outcome measures, incidences adverse events between COPD undergoing ELVR either a partial pressure carbon dioxide...
C-C-chemokine receptors (CCRs) are expressed on a variety of immune cells and play an important role in many processes, particularly leukocyte migration. Comprehensive preclinical research demonstrated CCR2/CCR5-dependent pathways as pivotal for the pathophysiology severe COVID-19. Here we report human data use chemokine receptor inhibitor patients with COVID-19.Interim results 2:1 randomised, placebo-controlled, investigator-initiated trial CCR2/CCR5-inhibitor Cenicriviroc (CVC) 150 mg BID...
Abstract Purpose Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide causing a global health emergency. Pa-COVID-19 aims to provide comprehensive data on clinical course, pathophysiology, immunology and outcome of COVID-19, in order identify prognostic biomarkers, scores, therapeutic targets for improved management preventive interventions. Methods is prospective observational cohort study patients with confirmed SARS-CoV-2 infection treated at Charité -...
Endoscopic lung volume reduction (ELVR) with endobronchial valves (EBV) has been shown to improve pulmonary function, quality of life, and exercise capacity in a wide range COPD patients [1-5]. Nevertheless, some show severe complications after valve insertion or cannot sufficiently benefit from ELVR. In those patients, reversibility ELVR EBV is an important advantage compared other techniques reduction. data supporting removal as being safe procedure are still lacking.To answer the...
Abstract Global healthcare systems are challenged by the COVID-19 pandemic. There is a need to optimize allocation of treatment and resources in intensive care, as clinically established risk assessments such SOFA APACHE II scores show only limited performance for predicting survival severely ill patients. Comprehensively capturing host physiology, we speculated that proteomics combination with new data-driven analysis strategies could produce generation prognostic discriminators. We studied...
Endobronchial valve therapy has proven to reduce lung hyperinflation and decrease disease burden in patients with severe emphysema. Exclusion of collateral ventilation (CV) the targeted lobe by using an endobronchial assessment system (Chartis; PulmonX, Drive Redwood City, CA, USA) combination software-based fissure integrity analysis (FCS [fissure completeness score]) computed tomography scans are established tools select appropriate for treatment. So far, there is no conclusive evidence if...